1788872-06-9
1788872-06-9
Chemical Structure
Nav1.7-IN-3
- CAS No.: 1788872-06-9
- Formula:C17H20ClFN4O2S2
- Molecular Weight:430.95
IUPAC Name: 5-chloro-2-fluoro-4-(((tetrahydro-1H-pyrrolizin-7a(5H)-yl)methyl)amino)-N-(thiazol-2-yl)benzenesulfonamide
InChIKey: XFWKBJBSEOZBRA-UHFFFAOYSA-N
SMILES: FC1=C(S(=O)(NC2=NC=CS2)=O)C=C(Cl)C(NCC34CCCN3CCC4)=C1
Biological Activity: Nav1.7-IN-3 is a selective, orally bioavailable voltage-gated sodium channel Nav1.7 inhibitor with an IC50 of 8 nM. Pain relief. Limited CNS penetration[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Nav1.7-IN-3 | 98.21% | Nav1.7-IN-3 is a selective, orally bioavailable voltage-gated sodium channel Nav1.7 inhibitor with an IC50 of 8 nM. Pain relief. Limited CNS penetration. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Nav1.7-IN-3 (Standard) | ≥98% | Nav1.7-IN-3 (Standard) is the analytical standard of Nav1.7-IN-3 (HY-101789). This product is intended for research and analytical applications. Nav1.7-IN-3 is a selective, orally bioavailable voltage-gated sodium channel Nav1.7 inhibitor with an IC50 of 8 nM. Pain relief. Limited CNS penetration. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ABT-639 hydrochloride | ABT-639 hydrochloride is a novel, peripherally acting, selective T-type Ca2+ channel blocker. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Aneratrigine | 99.60% | Aneratrigine is a selective Nav1.7 inhibitor with an IC50 of 19 nM. Aneratrigine is applicable for pain-related research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Aneratrigine hydrochloride | Aneratrigine hydrochloride is a selective Nav1.7 inhibitor with an IC50 of 19 nM. Aneratrigine hydrochloride is applicable for pain-related research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
BVT-2733 hydrochloride | BVT-2733 hydrochloride is a potent, selective and orally active nonsteroidal 11β-HSD1 inhibitor. BVT-2733 hydrochloride is more potent against mouse 11β-HSD1 enzyme (IC50=96 nM) than against human 11β-HSD1 enzyme (IC50=3341 nM). BVT-2733 hydrochloride has the potential to be used in the study of arthritis and obesity-related diseases. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
BVT 2733 (Standard) | ≥98% | BVT 2733 (Standard) is the analytical standard of BVT 2733. This product is intended for research and analytical applications. BVT 2733 is a potent, selective, and orally active non-steroidal 11β-hydroxydehydrogenase 1 (11β-HSD1) inhibitor. BVT 2733 is potently against the mouse enzyme (IC50=96 nM) over the human enzyme (IC50=3341 nM). BVT 2733 has the potential for the study of arthritis and obesity related disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
BVT-3498 | BVT-3498 (AMG-311) is an inhibitor for 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
GNE-3565 | GNE-3565 is an arylsulfonamide class NaV1.7 inhibitor with subnanomolar channel blockage and mixed subtype selectivity.GNE-3565 can be used for the research of pain. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Sodium Channel-IN-8 | Sodium Channel-IN-8 (Example 96) is a voltage-gated sodium channel (NaV1.7) inhibitor.Sodium Channel-IN-8 can be used for the research of pain. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ABT-639 | 98.67% | ABT-639 is a novel, peripherally acting, selective T-type Ca2+ channel blocker. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Succinylsulfathiazole | 99.75% | Succinylsulfathiazole (Succinylsulphathiazole) is a long-acting sulfonamide antibiotic with localized gut-specific antibacterial activity and is orally active. Succinylsulfathiazole inhibits bacterial folate synthesis, reduces coliform counts, suppresses intestinal bacterial growth and vitamin biosynthesis, and depletes gut folate-producing bacteria. Succinylsulfathiazole modulates hepatic mTOR signaling, diminishes cecal fermentation, decreases hepatic folate levels and total folate excretion, elevates nitrogen excretion and reduces the fermentability of certain dietary fibers. Succinylsulfathiazole induces folate deficiency and triggers biotin- and folate-related nutritional deficiency symptoms in rats and C57BL/6 mice. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
